No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer

R. T. Eagan, S. Frytak, R. E. Lee, Terry M Therneau, R. L. Richardson, E. T. Creagan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A randomized trial of extensive small cell lung cancer (SMCLC) without CNS metastases comparing combination chemotherapy with the three-drug combination of vincristine, doxorubicin, and cyclophosphamide (VAC) versus a program using six drugs and starting with VAC plus Lomustine (CCNU) and etoposide (VAC-LE) was begun. After three cycles, patients without progression of disease were bronchoscoped and then randomized to the original chemotherapy program and prophylactic cranial irradiation (PCI) with or without thoracic radiation therapy (TRT). Patients with CNS metastases at diagnosis were treated with the VAC-LE program. At initial evaluation of 17 patients on VAC, and 18 without CNS metastases, and 10 with CNS metastases on VAC-LE, a statistical superiority for the VAC-LE over VAC was noted. Patients on VAC-LE (in CNS negative patients) had a higher regression rate (89% vs. 82%, 7 CR vs. 0%); a higher negative second bronchoscopy rate (69 vs. 50%); and better median (12.3 vs. 6.8 months), 2-year (14 vs. 0%), and overall survival rates (p = 0.005) than did patients on VAC. Even the VAC-LE, CNS positive patients had higher CR (20 vs. 0%), median (8.6 vs. 6.8 months), and 2-year survival rates (10 vs. 0%) than did VAC patients without CNS metastases.

Original languageEnglish (US)
Pages (from-to)141-145
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume10
Issue number2
StatePublished - 1987
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Vincristine
Doxorubicin
Cyclophosphamide
Radiotherapy
Thorax
Neoplasm Metastasis
Lomustine
Survival Rate
Cranial Irradiation
Bronchoscopy
Etoposide
Drug Combinations
Combination Drug Therapy
Disease Progression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer. / Eagan, R. T.; Frytak, S.; Lee, R. E.; Therneau, Terry M; Richardson, R. L.; Creagan, E. T.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 10, No. 2, 1987, p. 141-145.

Research output: Contribution to journalArticle

@article{edd7b336000747aa8f7dade863e470ee,
title = "No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer",
abstract = "A randomized trial of extensive small cell lung cancer (SMCLC) without CNS metastases comparing combination chemotherapy with the three-drug combination of vincristine, doxorubicin, and cyclophosphamide (VAC) versus a program using six drugs and starting with VAC plus Lomustine (CCNU) and etoposide (VAC-LE) was begun. After three cycles, patients without progression of disease were bronchoscoped and then randomized to the original chemotherapy program and prophylactic cranial irradiation (PCI) with or without thoracic radiation therapy (TRT). Patients with CNS metastases at diagnosis were treated with the VAC-LE program. At initial evaluation of 17 patients on VAC, and 18 without CNS metastases, and 10 with CNS metastases on VAC-LE, a statistical superiority for the VAC-LE over VAC was noted. Patients on VAC-LE (in CNS negative patients) had a higher regression rate (89{\%} vs. 82{\%}, 7 CR vs. 0{\%}); a higher negative second bronchoscopy rate (69 vs. 50{\%}); and better median (12.3 vs. 6.8 months), 2-year (14 vs. 0{\%}), and overall survival rates (p = 0.005) than did patients on VAC. Even the VAC-LE, CNS positive patients had higher CR (20 vs. 0{\%}), median (8.6 vs. 6.8 months), and 2-year survival rates (10 vs. 0{\%}) than did VAC patients without CNS metastases.",
author = "Eagan, {R. T.} and S. Frytak and Lee, {R. E.} and Therneau, {Terry M} and Richardson, {R. L.} and Creagan, {E. T.}",
year = "1987",
language = "English (US)",
volume = "10",
pages = "141--145",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - No routine role for vincristine, adriamycin, and cyclophosphamide (VAC) or thoracic radiation therapy in extensive stage small cell lung cancer

AU - Eagan, R. T.

AU - Frytak, S.

AU - Lee, R. E.

AU - Therneau, Terry M

AU - Richardson, R. L.

AU - Creagan, E. T.

PY - 1987

Y1 - 1987

N2 - A randomized trial of extensive small cell lung cancer (SMCLC) without CNS metastases comparing combination chemotherapy with the three-drug combination of vincristine, doxorubicin, and cyclophosphamide (VAC) versus a program using six drugs and starting with VAC plus Lomustine (CCNU) and etoposide (VAC-LE) was begun. After three cycles, patients without progression of disease were bronchoscoped and then randomized to the original chemotherapy program and prophylactic cranial irradiation (PCI) with or without thoracic radiation therapy (TRT). Patients with CNS metastases at diagnosis were treated with the VAC-LE program. At initial evaluation of 17 patients on VAC, and 18 without CNS metastases, and 10 with CNS metastases on VAC-LE, a statistical superiority for the VAC-LE over VAC was noted. Patients on VAC-LE (in CNS negative patients) had a higher regression rate (89% vs. 82%, 7 CR vs. 0%); a higher negative second bronchoscopy rate (69 vs. 50%); and better median (12.3 vs. 6.8 months), 2-year (14 vs. 0%), and overall survival rates (p = 0.005) than did patients on VAC. Even the VAC-LE, CNS positive patients had higher CR (20 vs. 0%), median (8.6 vs. 6.8 months), and 2-year survival rates (10 vs. 0%) than did VAC patients without CNS metastases.

AB - A randomized trial of extensive small cell lung cancer (SMCLC) without CNS metastases comparing combination chemotherapy with the three-drug combination of vincristine, doxorubicin, and cyclophosphamide (VAC) versus a program using six drugs and starting with VAC plus Lomustine (CCNU) and etoposide (VAC-LE) was begun. After three cycles, patients without progression of disease were bronchoscoped and then randomized to the original chemotherapy program and prophylactic cranial irradiation (PCI) with or without thoracic radiation therapy (TRT). Patients with CNS metastases at diagnosis were treated with the VAC-LE program. At initial evaluation of 17 patients on VAC, and 18 without CNS metastases, and 10 with CNS metastases on VAC-LE, a statistical superiority for the VAC-LE over VAC was noted. Patients on VAC-LE (in CNS negative patients) had a higher regression rate (89% vs. 82%, 7 CR vs. 0%); a higher negative second bronchoscopy rate (69 vs. 50%); and better median (12.3 vs. 6.8 months), 2-year (14 vs. 0%), and overall survival rates (p = 0.005) than did patients on VAC. Even the VAC-LE, CNS positive patients had higher CR (20 vs. 0%), median (8.6 vs. 6.8 months), and 2-year survival rates (10 vs. 0%) than did VAC patients without CNS metastases.

UR - http://www.scopus.com/inward/record.url?scp=0023140581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023140581&partnerID=8YFLogxK

M3 - Article

C2 - 3031976

AN - SCOPUS:0023140581

VL - 10

SP - 141

EP - 145

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 2

ER -